Oventus Medical Ltd. announced a succession plan which would see Dr. Chris Hart transition out of the role of Chief Executive Officer (CEO) and Mr. John Cox appointed as the new CEO to lead Oventus through the next chapter of providing life-changing treatment to Obstructive Sleep Apnoea (OSA) patients. Under the transition, John Cox will become the CEO, with full accountability for the performance and growth of the business. He brings a strong track record in successfully commercialising medtech therapeutics, including OSA technologies.